Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Novo Nordisk A/S, headquartered in Bagsvaerd, Denmark, is a dominant player in the GLP-1 receptor agonist market
At 40 mg/mL, those same 10 units deliver 160% of the starting dose, which is well above the recommended initial amount
These effects can help clients reduce caloric intake, working alongside lifestyle changes such as diet and exercise to promote significant weight loss
Supplied as a stable freeze-dried powder, it is strictly intended for laboratory and in-vitro research applications only
US$ 27.45
US$ 27.92
US$ 29.77
US$ 22.85
US$ 23.58
US$ 27.28
